Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).
Gunter Von Minckwitz
Consultant or Advisory Role - AbbVie
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Joyce O'Shaughnessy
No relevant relationships to disclose
Eric P. Winer
Research Funding - Genentech
Norman Wolmark
Consultant or Advisory Role - Roche (U); Sanofi (U)
Research Funding - NCI
Charles E. Geyer
No relevant relationships to disclose
Jens Bodo Huober
No relevant relationships to disclose
Sibylle Loibl
Honoraria - AbbVie
William M. Sikov
Consultant or Advisory Role - AbbVie (U)
Michael Untch
No relevant relationships to disclose
Mark D. McKee
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Vincent L. Giranda
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Hope S. Rugo
No relevant relationships to disclose